|
1
|
Buonaguro L, Petrizzo A, Tagliamonte M,
Tornesello ML and Buonaguro FM: Challenges in cancer vaccine
development for hepatocellular carcinoma. J Hepatol. 59:897–903.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu Q, Liu X, Zheng X, Yao Y, Wang M and
Liu Q: The transcriptional activity of Gli1 is negatively regulated
by AMPK through Hedgehog partial agonism in hepatocellular
carcinoma. Int J Mol Med. 34:733–741. 2014.PubMed/NCBI
|
|
3
|
Kiang JG and Tsokos GC: Heat shock protein
70 kDa: molecular biology, biochemistry, and physiology. Pharmacol
Ther. 80:183–201. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Welch WJ: Mammalian stress response: cell
physiology, structure/function of stress proteins, and implications
for medicine and disease. Physiol Rev. 72:1063–1081.
1992.PubMed/NCBI
|
|
5
|
Milicevic Z, Bogojevic D, Mihailovic M,
Petrovic M and Krivokapic Z: Molecular characterization of hsp90
isoforms in colorectal cancer cells and its association with tumour
progression. Int J Oncol. 32:1169–1178. 2008.PubMed/NCBI
|
|
6
|
Nimmanapalli R, O'Bryan E and Bhalla K:
Geldanamycin and its analogue
17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and
induces apoptosis and differentiation of Bcr-Abl-positive human
leukemic blasts. Cancer Res. 61:1799–1804. 2001.PubMed/NCBI
|
|
7
|
Pascale RM, Simile MM, Calvisi DF, Frau M,
Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR,
Thorgeirsson SS and Feo F: Role of HSP90, CDC37, and CRM1 as
modulators of P16(INK4A) activity in rat liver carcinogenesis and
human liver cancer. Hepatology. 42:1310–1319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yano M, Naito Z, Tanaka S and Asano G:
Expression and roles of heat shock proteins in human breast cancer.
Jpn J Cancer Res. 87:908–915. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu QR, Liu X, Yao YM and Liu QG:
Expression of HSP90 and HIF-1α in human colorectal cancer tissue
and its significance. Asian Pac J Trop Med. 7:720–724. 2014.
View Article : Google Scholar
|
|
10
|
Palsson-McDermott EM, Curtis AM, Goel G,
Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR,
Domingo-Fernandez R, Johnston DG, et al: Pyruvate kinase M2
regulates Hif-1α activity and IL-1β induction and is a critical
determinant of the Warburg effect in LPS-activated macrophages.
Cell Metabolism. 21:65–80. 2015. View Article : Google Scholar
|
|
11
|
Wang GL, Jiang B-H, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
|
|
12
|
Krishnamachary B, Berg-Dixon S, Kelly B,
Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P
and Semenza GL: Regulation of colon carcinoma cell invasion by
hypoxia-inducible factor 1. Cancer Res. 63:1138–1143.
2003.PubMed/NCBI
|
|
13
|
Mizukami Y, Li J, Zhang X, Zimmer MA,
Iliopoulos O and Chung DC: Hypoxia-inducible factor-1-independent
regulation of vascular endothelial growth factor by hypoxia in
colon cancer. Cancer Res. 64:1765–1772. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao D, Hou M, Guan YS, Jiang M, Yang Y and
Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer:
association with clinical outcomes and prognostic implications. BMC
Cancer. 9:4322009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C,
Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and
induces apoptosis and growth arrest by regulating YAP abundance in
hepatocellular carcinoma. Mol Cancer. 13:110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riis ML, Lüders T, Nesbakken AJ, Vollan
HS, Kristensen V and Bukholm IR: Expression of BMI-1 and Mel-18 in
breast tissue-a diagnostic marker in patients with breast cancer.
BMC Cancer. 10:6862010. View Article : Google Scholar
|
|
17
|
Tu K, Zheng X, Zan X, Han S, Yao Y and Liu
Q: Evaluation of Fbxw7 expression and its correlation with the
expression of c-Myc, cyclin E and p53 in human hepatocellular
carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Q, Liu X, Zheng X, Yao Y and Liu Q:
PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol
Lett. 8:1973–1979. 2014.PubMed/NCBI
|
|
20
|
Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao
J, Yao Y and Liu Q: Recombinant human adenovirus-p53 injection
induced apoptosis in hepatocellular carcinoma cell lines mediated
by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One.
8:e685742013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng X, Vittar NB, Gai X,
Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler
AL, Elsawa SF, Vrabel AM and Shire AM: The transcription factor
GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a
SNAI1-dependent mechanism. PLoS One. 7:e495812012. View Article : Google Scholar
|
|
22
|
Cao S, Yang S, Wu C, Wang Y, Jiang J and
Lu Z: Protein expression of hypoxia-inducible factor-1 alpha and
hepatocellular carcinoma: a systematic review with meta-analysis.
Clin Res Hepatol Gastroenterol. 38:598–603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue N, Jin J, Liu D, Yan R, Zhang S, Yu X
and Chen X: Antiproliferative effect of HSP90 inhibitor Y306zh
against pancreatic cancer is mediated by interruption of AKT and
MAPK signaling pathways. Curr Cancer Drug Targets. 14:671–683.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haarberg HE, Paraiso KH, Wood E, Rebecca
VW, Sondak VK, Koomen JM and Smalley KS: Inhibition of Wee1, AKT,
and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an
in vivo model of NRAS-mutant melanoma. Mol Cancer Ther. 12:901–912.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu XG, Xing CG, Feng YZ, Chen J and Deng
C: Clinical significance of immunohistochemical expression of
hypoxia-inducible factor-1alpha as a prognostic marker in rectal
adenocarcinoma. Clin Colorectal Cancer. 5:350–353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu YV and Semenza GL: RACK1 vs. HSP90:
competition for HIF-1 alpha degradation vs. stabilization. Cell
Cycle. 6:656–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bagatell R and Whitesell L: Altered Hsp90
function in cancer: a unique therapeutic opportunity. Mol Cancer
Ther. 3:1021–1030. 2004.PubMed/NCBI
|
|
28
|
Goetz MP, Toft DO, Ames MM and Erlichman
C: The Hsp90 chaperone complex as a novel target for cancer
therapy. Ann Oncol. 14:1169–1176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Workman P, Burrows F, Neckers L and Rosen
N: Drugging the cancer chaperone HSP90: Combinatorial therapeutic
exploitation of oncogene addiction and tumor stress. Ann NY Acad
Sci. 1113:202–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qi XL, Bo AH, Yue SC, Wang CY and Liu HB:
Heat shock protein 90 mrna expressed in adenocarcinoma and adenoma
of significance. Proceed Military Academy Medical Sci. 30:351–353.
2011.
|
|
32
|
Bo AH, Dai J, Li SG, Zuo DS, Chen XL, Yan
YJ, et al: HSP90 mRNA expressed in stomach and large intestine
cancer research. Chin J Histochem Cytochem. 14:213–216. 2011.
|
|
33
|
Pick E, Kluger Y, Giltnane JM, Moeder C,
Camp RL, Rimm DL and Kluger HM: High HSP90 expression is associated
with decreased survival in breast cancer. Cancer Res. 67:2932–2937.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kang GH, Lee EJ, Jang KT, Kim KM, Park CK,
Lee CS, Kang DY, Lee SH, Sohn TS and Kim S: Expression of HSP90 in
gastrointestinal stromal tumours and mesenchymal tumours.
Histopathology. 56:694–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q
and Liu H: 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces
mitochondria-mediated apoptosis through downregulation of Mcl-1 in
human hepatocel-lular carcinoma cells. J Bioenerg Biomembr.
47:373–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
